3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
4
Recurrence
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma, B-Cell
2
Burkitt Lymphoma
2
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Diseases
1
Anemia
1
Amyloidosis
1
Interventions
tisagenlecleucel
2
fludarabine
2
blinatumomab
2
Cyclophosphamide
2
zanubrutinib
1
selinexor
1
revumenib
1
niraparib
1
nilotinib
1
ivosidenib
1
imetelstat
1
ibrutinib
1
entrectinib
1
dostarlimab
1
brexucabtagene autoleucel
1
avapritinib
1
asciminib
1
Standard of Care
1
Paclitaxel
1
Imatinib Mesylate
1
GRN163L peptide
1
Drug Therapy
1
Dexamethasone
1
Dasatinib
1
Carboplatin
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has announcements
×
Recurrence
×
Cyclophosphamide
×
Clear all
NCT04245839
2025-11-05
TRANSCEND FL
Celgene
Phase 2
Active not recruiting
276 enrolled
2 FDA
NCT02614066
2024-11-19
ZUMA-3
Gilead Sciences
Phase 1/2
Completed
125 enrolled
27 charts
1 FDA